Key Findings:  For patients with kidney failure, this review finds that cannabinoids, although showing promise in alleviating symptoms, based on the current evidence, should not be prescribed until further high-quality studies are done.
Type of Study:  Meta-analysis
Study Result:  Negative
Study Location(s):  Australia, Canada
Year of Pub:  2022
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1, CB2